For 55 years, the federal government classified psilocybin, MDMA, LSD, and ibogaine as Schedule I substances — drugs with no accepted medical use. On April 18, 2026, President Trump signed an executive order titled 'Accelerating Medical Treatments for Serious Mental Illness,' directing the Food and Drug Administration (FDA) to expedite clinical trials of those same substances for treating post-traumatic stress disorder (PTSD) in veterans. The order, whose signing ceremony included podcaster Joe Rogan and former Navy SEAL Marcus Luttrell, was driven substantially by Health and Human Services Secretary Robert F. Kennedy Jr. It makes $50 million in federal funding through the Advanced Research Projects for Health (ARPA-H) available for state-level ibogaine research — matched by state funds — and extends the Right to Try law to allow seriously ill patients to access psychedelics still under investigation. Within hours of the signing, FDA Commissioner Marty Makary announced that the agency would issue 'national priority' review vouchers for three psilocybin-class drugs, a first for any psychedelic substance, with decisions possible as early as summer 2026. The FDA also announced steps to clear the way for the first-ever US human trials of ibogaine.
The order does not legalize psychedelics or bypass FDA approval, but it accelerates the regulatory pipeline through faster trial guidance, federal research dollars, and a directive to streamline rescheduling for any psychedelic that wins FDA approval. Several of these substances already carry the FDA's 'breakthrough therapy' designation, meaning early clinical evidence shows substantial improvement over existing treatments. The move comes 20 months after the FDA rejected MDMA-assisted therapy for PTSD in August 2024, a decision that galvanized veteran advocacy groups and bipartisan congressional support for alternative pathways. Legal analysts at the Harvard Law School Petrie-Flom Center immediately raised questions about whether the Right to Try Act can be extended to Schedule I substances without Drug Enforcement Administration (DEA) rescheduling, and safety experts flagged ibogaine's known risk of fatal cardiac arrhythmias — a concern serious enough that the National Institutes of Health (NIH) discontinued ibogaine research in the 1990s specifically because of it.
Why it matters
Millions of veterans with treatment-resistant PTSD may gain access to therapies that have been federally prohibited for over five decades.
Trump signs executive order expediting psychedelic research
Executive Action
President Trump signed an executive order directing the FDA to issue new guidance expediting clinical trials of psilocybin, MDMA, ibogaine, and LSD for veteran PTSD, making $50 million available for state-level ibogaine research and opening a Right to Try pathway for seriously ill patients.
FDA Commissioner announces priority review vouchers for psilocybin drugs and US ibogaine trial clearance
Regulatory
FDA Commissioner Marty Makary announced that the agency would issue 'national priority' review vouchers for three serotonin 2a agonist drugs — a class that includes psilocybin — marking the first time the FDA has fast-tracked any psychedelic substance for priority review. Decisions could come as early as summer 2026. Makary also said the FDA is taking steps to clear the way for the first-ever human clinical trials of ibogaine on US soil.
Veterans Exploring Treatment Solutions (VETS), a nonprofit connecting veterans with psychedelic therapy, issued a formal statement applauding the executive order and calling on the government to accelerate scientific investment in ibogaine research for PTSD, traumatic brain injury, and addiction.
Harvard Law School legal analysts flag Schedule I conflict with Right to Try extension
Legal
Professors I. Glenn Cohen and Mason Marks of the Harvard Law School Petrie-Flom Center published a legal analysis warning that extending the Right to Try Act to Schedule I substances like psilocybin and ibogaine is legally contested, because the Act was designed for investigational drugs under FDA review — not substances still federally classified as having no accepted medical use.
FDA rejects MDMA-assisted therapy for PTSD
Regulatory
The FDA formally rejected Lykos Therapeutics' application for MDMA-assisted therapy, following the advisory committee's recommendation. The rejection galvanized veteran advocacy groups and bipartisan congressional support for alternative pathways.
FDA advisory committee votes against MDMA therapy approval
Regulatory
An FDA advisory committee voted against recommending approval of MDMA-assisted therapy for PTSD, citing concerns about clinical trial methodology, inadequate blinding, and potential risks of abuse.
Colorado voters approve psychedelic access program
Legislation
Colorado passed Proposition 122, decriminalizing certain natural psychedelics and directing the state to create a regulated access program for psilocybin therapy.
Oregon passed Measure 109, creating the first state-regulated psilocybin therapy program in the United States. Licensed service centers began operating in 2023.
FDA grants psilocybin breakthrough therapy designation
Regulatory
The FDA granted breakthrough therapy designation to psilocybin for treatment-resistant depression, developed by Compass Pathways. A second designation followed in 2019 for major depressive disorder via the Usona Institute.
Trump signs Right to Try Act
Legislation
President Trump signed the Right to Try Act, allowing terminally ill patients to access investigational drugs that have completed Phase 1 trials without full FDA approval. The law's application to psychedelics was not envisioned at the time.
FDA grants MDMA breakthrough therapy designation for PTSD
Regulatory
The FDA designated MDMA-assisted therapy as a breakthrough therapy for PTSD, signaling that preliminary clinical evidence showed it may offer substantial improvement over existing treatments and expediting its development.
Rick Doblin founds MAPS to pursue legal psychedelic medicine
Organization
Doblin founded the Multidisciplinary Association for Psychedelic Studies with the explicit long-term goal of making MDMA a legal prescription medicine through the FDA approval process.
MDMA added to Schedule I on emergency basis
Regulation
The Drug Enforcement Administration (DEA) placed MDMA into Schedule I using emergency scheduling authority, despite objections from researchers and a DEA administrative law judge who recommended Schedule III.
Controlled Substances Act classifies psychedelics as Schedule I
Legislation
President Nixon signed the Controlled Substances Act, placing psilocybin, LSD, and other psychedelics into Schedule I — the most restrictive category, reserved for drugs deemed to have no accepted medical use and high abuse potential. This effectively halted decades of psychiatric research.
Scenarios
Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.
Log in to predict. Track your picks, climb the leaderboard.Log inSign Up
1
FDA approves first psychedelic therapy, rescheduling follows
Expedited FDA guidance leads to faster, better-designed clinical trials. One or more psychedelic substances — most likely psilocybin for depression or MDMA for PTSD — win FDA approval within 2-4 years. The executive order's rescheduling directive then moves the approved substance from Schedule I to a lower schedule, creating a legal framework for prescription use. This would represent the first federally approved psychedelic medicine since the 1970 Controlled Substances Act.
Discussed by: Psychedelic medicine researchers, drug policy analysts, and industry advocates
Consensus—
2
Right to Try becomes primary access channel, bypassing full approval
Rather than waiting years for full FDA approval, veterans and seriously ill patients begin accessing psychedelics through the Right to Try pathway. State-level ibogaine programs, funded by the $50 million allocation, create a patchwork of legal access. This de facto normalizes psychedelic therapy before the FDA formally approves any substance, creating political momentum that makes full prohibition untenable. Critics warn that safety monitoring in this scenario would be minimal compared to the clinical trial process.
Discussed by: Veteran advocacy groups, libertarian-leaning policy analysts, and some Republican lawmakers
Consensus—
3
FDA independence concerns stall implementation
The FDA pushes back on executive pressure to expedite reviews, arguing that the MDMA rejection demonstrated real methodological problems that cannot be waved away by executive order. Legal challenges may arise over whether the Right to Try Act can be applied to Schedule I substances without DEA rescheduling. Implementation stalls in bureaucratic and legal disputes, with the executive order's practical impact limited to the $50 million ibogaine research allocation.
Discussed by: Medical establishment figures, FDA staff, and some Democratic lawmakers
Consensus—
4
Safety incident triggers political reversal
Expanded access through Right to Try or state programs leads to a serious adverse event — ibogaine carries known cardiac risks, and MDMA has abuse potential. A high-profile death or injury generates political backlash, particularly if it involves a veteran. The incident is used to justify tightening restrictions, potentially setting back the broader psychedelic therapy movement by years. This scenario echoes how individual incidents in the 1960s contributed to the blanket prohibition that followed.
Discussed by: FDA safety officials, addiction medicine specialists, and some psychiatrists
Nixon's Controlled Substances Act ends first wave of psychedelic research (1970)
October 1970
What Happened
Between the 1950s and late 1960s, researchers conducted over 1,000 clinical studies on LSD and other psychedelics, treating an estimated 40,000 patients for conditions including alcoholism, depression, and end-of-life anxiety. The Controlled Substances Act placed these substances into Schedule I, effectively criminalizing all research and therapeutic use. The decision was driven more by the association of psychedelics with the counterculture movement than by clinical safety data.
Outcome
Short Term
Virtually all psychedelic research stopped. Scientists who had spent careers studying these compounds abandoned the field or moved abroad.
Long Term
A 40-year gap in psychedelic research. When trials resumed in the 2000s, researchers had to rebuild methodology and institutional knowledge from scratch.
Why It's Relevant Today
The current executive order represents the most significant federal reversal of the 1970 prohibition framework. Understanding that the original scheduling was politically rather than scientifically driven helps explain why breakthrough therapy designations and clinical evidence have not been sufficient to change policy through normal regulatory channels.
FDA rejection of MDMA therapy despite breakthrough designation (2024)
June–August 2024
What Happened
After 38 years and over $100 million in research, MAPS' pharmaceutical arm Lykos Therapeutics submitted an application for MDMA-assisted therapy for PTSD based on two Phase 3 trials showing significant symptom reduction. An FDA advisory committee voted 9-2 against recommending approval, citing concerns about study blinding (participants could often tell whether they received MDMA), therapist influence on outcomes, and inadequate safety data on abuse potential. The FDA followed the committee's recommendation and rejected the application in August 2024.
Outcome
Short Term
Lykos Therapeutics faced financial uncertainty. Veteran advocates who had expected approval felt betrayed by the regulatory process.
Long Term
The rejection shifted advocacy strategy from working within the FDA system to seeking political and executive intervention, directly contributing to the conditions that produced the April 2026 executive order.
Why It's Relevant Today
The MDMA rejection is the proximate cause of the executive order. It demonstrated that even with breakthrough therapy designation and positive clinical trial results, the standard FDA pathway could not deliver timely access — creating the political demand for an alternative approach.
Right to Try Act expands experimental drug access (2018)
May 2018
What Happened
President Trump signed the Right to Try Act, allowing patients with life-threatening conditions to request access to investigational drugs that had completed Phase 1 trials but not yet received full FDA approval. The law was championed by libertarian-leaning groups and the Goldwater Institute, and passed the Senate unanimously. In practice, relatively few patients used the pathway — most pharmaceutical companies preferred the existing FDA expanded access program.
Outcome
Short Term
Limited practical impact. Most drug companies continued routing compassionate use requests through the FDA's existing expanded access program.
Long Term
Established a legal precedent for patients to access unapproved drugs outside the FDA framework, which the 2026 executive order now extends to psychedelic substances.
Why It's Relevant Today
The executive order's extension of Right to Try to psychedelics tests the law's boundaries significantly. The original act was designed for terminally ill patients seeking experimental cancer drugs — applying it to Schedule I substances for PTSD represents a novel and potentially contested interpretation.
